UCLA Center for Cancer Prevention and Control Research, UCLA Kaiser Permanente Center for Health Equity, Department of Health Policy and Management, Fielding School of Public Health and Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, California.
Division of Health Equities, Department of Population Sciences, City of Hope, Duarte, California.
Cancer Epidemiol Biomarkers Prev. 2022 Oct 4;31(10):1952-1958. doi: 10.1158/1055-9965.EPI-22-0156.
Human papillomavirus (HPV) vaccines can significantly reduce the burden of HPV-associated cancers, but remain underutilized. We evaluated a multi-component, system-level intervention to improve HPV vaccination in a large Federally Qualified Health Center (FQHC) that serves a primarily low income Latino population.
From January 2015 through March 2017, we evaluated the effectiveness of a multi-component, system-level intervention to improve HPV vaccination rates in eight clinics randomly assigned to study condition (four intervention, four usual care). The intervention included parent reminders for HPV vaccine series completion, provider training, clinic-level audit and feedback, and workflow modifications to reduce missed opportunities for vaccination. Using a difference-in-differences approach, we compared HPV vaccination rates among patients, ages 11 to 17 during a 12-month preintervention period and a 15-month intervention period. Linear mixed models were used to estimate intervention effects on vaccine initiation and completion.
The sample included approximately 15,000 adolescents each quarter (range 14,773-15,571; mean age 14 years; 51% female, 88% Latino). A significantly greater quarterly increase in HPV vaccine initiation was observed for intervention compared with usual care clinics (0.75 percentage point greater increase, P < 0.001), corresponding to 114 additional adolescents vaccinated per quarter. The intervention led to a greater increase in HPV vaccine completion rates among boys (0.65 percentage point greater increase, P < 0.001), but not girls.
Our system-level intervention was associated with modest improvements in HPV vaccine initiation overall and completion among boys.
Study findings have implications for reducing HPV-related cancers in safety net populations.
人乳头瘤病毒(HPV)疫苗可以显著降低 HPV 相关癌症的负担,但使用率仍然较低。我们评估了一项多组分、系统级干预措施,以改善一家主要为低收入拉丁裔人群服务的大型联邦合格医疗中心(FQHC)的 HPV 疫苗接种率。
从 2015 年 1 月到 2017 年 3 月,我们评估了一项多组分、系统级干预措施在 8 个诊所中的有效性,这些诊所被随机分配到研究条件(4 个干预组,4 个常规护理组)。该干预措施包括家长提醒 HPV 疫苗系列完成、提供者培训、诊所级别的审计和反馈,以及工作流程修改,以减少错过接种疫苗的机会。我们使用差异中的差异方法,比较了在 12 个月的干预前和 15 个月的干预期间,年龄在 11 至 17 岁的患者中 HPV 疫苗接种率。线性混合模型用于估计干预对疫苗接种起始和完成的影响。
样本中每季度大约有 15000 名青少年(范围为 14773-15571;平均年龄 14 岁;51%为女性,88%为拉丁裔)。与常规护理诊所相比,干预组中 HPV 疫苗接种起始率的季度增长率显著更高(增加 0.75 个百分点,P < 0.001),相当于每季度增加 114 名青少年接种疫苗。干预措施导致男孩 HPV 疫苗接种完成率的增长幅度更大(增加 0.65 个百分点,P < 0.001),但女孩没有。
我们的系统级干预措施与 HPV 疫苗接种起始率的适度提高以及男孩 HPV 疫苗接种完成率的提高有关。
研究结果对减少安全网人群中 HPV 相关癌症有影响。